Work

AML-162: Efficacy and Safety of Venetoclax in Combination with Gilteritinib for Relapsed/Refractory FLT3-Mutated Acute Myeloid Leukemia: Updated Analyses of a Phase 1b Study

Year: 2021

Type: conference-abstract

Source: Clinical Lymphoma Myeloma & Leukemia

DOI: 10.1016/s2152-2650(21)01684-0

Authors: Jessica K. Altman, Naval Daver, Joseph Maly, Mark Levis, Ellen Ritchie, Mark Litzow, James McCloskey, Catherine C. Smith, Gary Schiller, Terrence Bradley, Ramon V. Tiu, Kiran Naqvi, Satya Siddani, Jing Wang, Paul Lee, Alexander E. Perl

Institutions: Northwestern University, Robert H. Lurie Comprehensive Cancer Center of Northwestern University, The University of Texas MD Anderson Cancer Center, Norton Healthcare, Johns Hopkins University, Sidney Kimmel Comprehensive Cancer Center, Weill Cornell Medicine, Mayo Clinic, Hackensack Meridian Health, University of California, San Francisco, UCSF Helen Diller Family Comprehensive Cancer Center, University of California, Los Angeles, University of Miami, Sylvester Comprehensive Cancer Center, Astellas Pharma (United States), Genentech, AbbVie (United States), Abramson Cancer Center, University of Pennsylvania

Language: English

Topic: Acute Myeloid Leukemia Research

Subfield: Hematology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W3196856914

Cites:

Cited by: 6

Related to: 10